These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24519508)

  • 21. Anterior chamber migration of intravitreal dexamethasone implant in glued intraocular lens.
    Kumar DA; Dhawan A; Narayanan S; Agarwal A
    Indian J Ophthalmol; 2019 Feb; 67(2):268-269. PubMed ID: 30672486
    [No Abstract]   [Full Text] [Related]  

  • 22. EFFICACY AND SAFETY OF DEXAMETHASONE INTRAVITREAL IMPLANT FOR PERSISTENT UVEITIC CYSTOID MACULAR EDEMA.
    Khurana RN; Porco TC
    Retina; 2015 Aug; 35(8):1640-6. PubMed ID: 25741813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phacoemulsification and intraocular lens implantation after inadvertent intracapsular injection of intravitreal dexamethasone implant.
    Ram J; Agarwal AK; Gupta A; Gupta A
    BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23235103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies.
    Khurana RN; Appa SN; McCannel CA; Elman MJ; Wittenberg SE; Parks DJ; Ahmad S; Yeh S
    Ophthalmology; 2014 Jan; 121(1):67-71. PubMed ID: 23890421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surgical intervention of steroid-induced ocular hypertension from Ozurdex.
    Sejpal P; Scott-Weideman J
    Optom Vis Sci; 2013 Jan; 90(1):e24-30. PubMed ID: 23241827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
    Bakri SJ; Omar AF
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):547-9. PubMed ID: 22537269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for and management of anterior chamber intravitreal dexamethasone implant migration.
    Röck D; Bartz-Schmidt KU; Röck T
    BMC Ophthalmol; 2019 May; 19(1):120. PubMed ID: 31138164
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Repositioning and follow-up of intralenticular dexamethasone implant.
    Munteanu M; Rosca C
    J Cataract Refract Surg; 2013 Aug; 39(8):1271-4. PubMed ID: 23889870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reliability and safety of intravitreal Ozurdex injections. The ZERO study].
    Schmitz K; Maier M; Clemens CR; Höhn F; Wachtlin J; Lehmann F; Bertelmann T; Rüdiger K; Horn M; Bezatis A; Spital G; Meyer CH;
    Ophthalmologe; 2014 Jan; 111(1):44-52. PubMed ID: 23559321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anterior Chamber Migration of Ozurdex Implants.
    Kayıkcıoğlu Ö; Doğruya S; Sarıgül C; Mayalı H; Kurt E
    Turk J Ophthalmol; 2020 Apr; 50(2):115-122. PubMed ID: 32367704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravitreal Dexamethasone Implant for the Treatment of Postoperative Macular Edema.
    Klamann A; Böttcher K; Ackermann P; Geerling G; Schargus M; Guthoff R
    Ophthalmologica; 2016; 236(4):181-185. PubMed ID: 27915343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of anterior chamber dislocation of dexamethasone implant.
    Kishore SA; Schaal S
    Ocul Immunol Inflamm; 2013; 21(1):90-1. PubMed ID: 23323589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Macular cytomegalovirus retinitis following dexamethasone intravitreal implant combined with phacoemulsification.
    Dogra M; Rohilla V; Dogra M; Singh R
    Indian J Ophthalmol; 2018 Sep; 66(9):1361-1363. PubMed ID: 30127173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scleral fixation of dexamethasone intravitreal implant (OZURDEX®) in a case of angle-supported lens implantation.
    Mateo C; Alkabes M; Burés-Jelstrup A
    Int Ophthalmol; 2014 Jun; 34(3):661-5. PubMed ID: 23928945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of dexamethasone implant along with phacoemulsification and intraocular lens implantation in children with juvenile idiopathic arthritis associated uveitis.
    Jinagal J; Gupta G; Agarwal A; Aggarwal K; Akella M; Gupta V; Suri D; Gupta A; Singh S; Ram J
    Indian J Ophthalmol; 2019 Jan; 67(1):69-74. PubMed ID: 30574896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study.
    Bellocq D; Korobelnik JF; Burillon C; Voirin N; Dot C; Souied E; Conrath J; Milazzo S; Massin P; Baillif S; Kodjikian L
    Br J Ophthalmol; 2015 Jul; 99(7):979-83. PubMed ID: 25583283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex®) on intraocular pressure in patients with macular edema.
    Mazzarella S; Mateo C; Freixes S; Burés-Jelstrup A; Rios J; Navarro R; García-Arumí J; Corcóstegui B; Arrondo E
    Ophthalmic Res; 2015; 54(3):143-9. PubMed ID: 26394206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Common and Rare Ocular Side-effects of the Dexamethasone Implant.
    Fassbender Adeniran JM; Jusufbegovic D; Schaal S
    Ocul Immunol Inflamm; 2017 Dec; 25(6):834-840. PubMed ID: 27379861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unintentional injection of a dexamethasone implant into the crystalline lens: a case report.
    Cervantes AL; Crim N; García-Arroyo S; Morales-Cantón V; Montoya RV
    Arq Bras Oftalmol; 2020 Jun; 83(3):246-249. PubMed ID: 32490978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Tolerability and short-term efficacy of the Ozurdex® dexamethasone intravitreal implant for treatment of uveitic cystoid macular edema: A retrospective study of 52 injections performed at the Clermont-Ferrand teaching hospital].
    Bernard Y; Bonnin N; Farguette F; Chiambaretta F
    J Fr Ophtalmol; 2016 Jan; 39(1):1-4. PubMed ID: 26616298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.